SAB Biotherapeutics up after treatment shows promise against Omicron in lab test

SAB Biotherapeutics

16/12/2021 11:26

** Shares of drug developer  SABS.O  rise 7.6% to $10.50
premarket
    ** Co says its experimental COVID-19 treatment, SAB-185,
retains neutralization activity against Omicron variant in lab
testing with in vitro pseudovirus model (https://refini.tv/32dhtPu)
    ** Data generated by scientists at U.S. FDA's Center for
Biologics Evaluation and Research
    ** SAB-185 is currently being evaluated in National
Institutes of Health-sponsored late-stage COVID-19 trial
    ** Co says additional analyses are ongoing, and the full
data set is being prepared for publication in the online life
sciences archive, bioRxiv


 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))